IP Library › Granted Patent US 11,524,070
Granted Patent B2
US 11,524,070 · App. 16/706,999 · Granted Dec 13, 2022

Manufacture of surfactant-containing compositions with enhanced stability

Inventor: Gottfried Kraus (Marburg, DE)
Assignee: NOVARTIS AG
A61K39/39A61K9/107A61K39/00A61K39/145A61K47/26B01D71/68C12N7/00A61K2039/55566B01D2325/022B01D2325/36C12N2760/16034
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,524,070
App. No.
16/706,999
Granted
Dec 13, 2022
Kind
B2
Abstract

Improved methods for the manufacture of pharmaceutical compositions comprising at least one surfactant, involving prefiltration of the surfactant prior to formulation into final products.

Claims (5)

1. A process for preparing a pharmaceutically acceptable composition comprising steps of: (a) filtering a polysorbate 80 through a filter membrane having a pore size between 5-50 μm, to provide purified polysorbate 80 as a filtrate; and (b) using the purified polysorbate 80 to formulate the pharmaceutically acceptable composition.

2. The process of claim 1 , wherein the purified polysorbate 80 contains less than 0.85 ppm acetaldehyde.

3. The process of claim 1 , wherein step (a) comprises:

filtering non-aqueous polysorbate 80 through a polypropylene filter having a pore size between 5-50 μm.

4. The process of claim 1 , wherein the purified polysorbate 80 is a bulk preparation of purified polysorbate 80 having a volume of at least 50 liters.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 19, 2024
From: NOVARTIS AG
To: SEQIRUS UK LIMITED
Reel/Frame 069642/0293 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2019
From: KRAUS, GOTTFRIED
To: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
Reel/Frame 051214/0546 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2019
From: NOVARTIS VACCINES AND DIAGNOSTICS GMBH
To: NOVARTIS AG
Reel/Frame 051214/0720 →
Priority Claims (1)
EP 14195981 · Dec 2, 2014 · regional
Continuity (3)
Continuation 16299372 · Mar 12, 2019
Continuation 15531487
Related Publication 20200353074A1 · Nov 12, 2020